CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective than an egg-based quadrivalent influenza vaccine over three consecutive influenza seasons in the U.